FDA-approved synthetic cannabinoids dronabinol and nabilone show some promise for pain conditions, but clinical evidence remains limited and inconsistent.
Pain specialists, pharmacologists, and patients exploring cannabinoid-based pain management options.
Two FDA-approved synthetic cannabinoids are being studied for pain, but evidence remains limited
What the researchers found
Dronabinol and nabilone, both THC-mimicking synthetics approved for nausea, are being investigated for neuropathic pain, spasticity-related pain, fibromyalgia, osteoarthritis, and postoperative pain. While some trials show modest benefit, the evidence base is thin and the complex signaling of the endocannabinoid system complicates drug development.
Why it matters
With the opioid crisis pushing demand for alternative pain treatments, understanding whether existing synthetic cannabinoids can fill that role is critical.
The numbers in context
Two FDA-approved synthetic cannabinoids (dronabinol and nabilone) discussed across multiple pain conditions including neuropathic pain, spasticity, fibromyalgia, and postoperative pain.
How the study worked
Narrative review examining the signaling mechanisms of FDA-approved synthetic cannabinoids, key clinical trials investigating their analgesic potential, and challenges in clinical translation.
What this study cannot tell us
Narrative review format means no systematic search or quality assessment. The clinical trial base for pain indications is limited. Approved indications remain restricted to nausea/appetite.
How to read the evidence
Narrative review format with limited clinical trial evidence for the specific pain indications discussed.
When this study was published
Published in 2024.
The bigger picture
Synthetic cannabinoids offer standardized dosing and known pharmacology compared to plant-derived products, but their clinical path to pain treatment has been slow due to the complexity of the endocannabinoid system.
Questions still open
- Could next-generation synthetic cannabinoids targeting specific receptor subtypes provide better pain relief with fewer side effects?
- How do synthetic cannabinoids compare to plant-derived cannabis products for pain management?
Common questions
Are synthetic cannabinoids approved for pain?
How do synthetic cannabinoids differ from plant cannabis?
Read the original research
The State of Synthetic Cannabinoid Medications for the Treatment of Pain.
CNS drugs, 38(8), 597-612
Citation
Maglaviceanu, Anca; Peer, Miki; Rockel, Jason; Bonin, Robert P; Fitzcharles, Mary-Ann; Ladha, Karim S; Bhatia, Anuj; Leroux, Timothy; Kotra, Lakshmi; Kapoor, Mohit; Clarke, Hance. (2024). The State of Synthetic Cannabinoid Medications for the Treatment of Pain.. CNS drugs, 38(8), 597-612. https://doi.org/10.1007/s40263-024-01098-9
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- THC and Painkillers: Opioid Interactions and the Harm Reduction Angle
- THC and Muscle Relaxers: What You Need to Know About Combining Them
- THC and Ibuprofen: Safe to Combine? What the Research Says